epcoritamab
genmab,abbvie
['lymsm', 'dlbcl', 'epcoritamab']
epcoritamab plus r-chop shows efficacy and tolerability as first-line treatment for high-risk dlbcl #asco22 #lymsm 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.